Recombinant gonadotrophins

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 106, Issue 3, 1999, Pages 188-196

  Hayden, Catherine J ^a   Balen, Adam H ^a   Rutherford, Anthony J ^a  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GONADOTROPIN; HUMAN MENOPAUSAL GONADOTROPIN; MONOCLONAL ANTIBODY; RECOMBINANT FOLLITROPIN; UROFOLLITROPIN;

ANOVULATION; CLINICAL TRIAL; DRUG POTENCY; DRUG PURIFICATION; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; EMBRYO TRANSFER; EXPRESSION VECTOR; GENE ISOLATION; GENETIC ENGINEERING; HORMONE ACTION; HUMAN; INFERTILITY; INTRAMUSCULAR DRUG ADMINISTRATION; NONHUMAN; OVULATION; PREGNANCY; PRIORITY JOURNAL; RECOMBINANT DNA TECHNOLOGY; REVIEW; SECOND MESSENGER; SUBCUTANEOUS DRUG ADMINISTRATION; SUPEROVULATION;

FEMALE; GONADOTROPINS, PITUITARY; HUMANS; INFERTILITY; MALE; RECOMBINANT PROTEINS; SUPEROVULATION;

EID: 0033031825     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/j.1471-0528.1999.tb08230.x     Document Type: Review

References (51)

1. Crowe SJ, Cushing H, Homans J. Experimental hypophysectomy. Johns Hopkins Med J 1910; 21: 127–169.
2. Zondek B, Aschheim S. Hypophysenvorderlappen und ovarium: bezeihungen der endokrinen drusen ZUT ovarialfunktion. In: Archiv fur Gynaecologie. Doderlein A. von Penham H, editors Berlin: Julius Springer Verlag, 1927: 1–145.
3. Cole HH, Hart GH. The potency of blood serum of mares in progressive stages of pregnancy in effecting the sexual maturity of the immature rat. Am J Physiol 1930; 93: 57–68.
4. Fevold HL, Hisaw FL, Leonard SL. The gonad stimulating and the luteinizing hormones of the anterior lobe of the hypothesis. Am J Physiol 1931; 97: 291–301.
5. Donini P, Montezemolo R. Rassegna di Clinica, Terapia e Scienze Affini (a publication of the Biologic Laboratories of the Instituto Serono) 1949; 48(143): 3–28.
6. Lunenfeld B, Sulmovici S, Rabau E, Eshkol A. L'induction de I'ovulation dans les amenorrhees hypophysaires par an traitment combine de gonadotrophines urinaires menopausiques et de gonadotrophines chorioniques. C R Soc Francaise de Gynecol 1962; 5: 1–6.
7. Kanel V, Rossetti, S. Mills C, editors. A Rile of Two Hormones: The Story of FSH and LH. Geneva: Ares Services SA, 1996: 29–30.
8. Hisaw FL. Hertz R. Hellbaum A. Fevold H. Luteinization of the ovary of the sexually immature monkey. Proc Soc Exp Biol Med 1932; 30:39–41.
9. Foster MA, Foster RC, Hisaw FL. The interrelationship of the pituitary sex hormones in ovulation, corpus luteum formation. and corus luteum secretion in the hypophysectomized rabbit. Endocrinology 1937; 21: 249–259.
10. Donini P, Puzzuoli D, D'Alessio I, Lunenfeld G, Eshkol A, Parlow AF. Purification and separation of follicle stimulating hormone (FSH) and luteinising hormone (LH) from human menopausal gonadotrophin (hMG): I. Separation of FSH and LH by electrophoresis, chromatography and gel filtration procedures. Acta Endocrinol 1966: 52:169–185.
11. Donini P, Puzzioli D, D'Alessio I, Lunenfeld G, Eshkol A, Parlow AF. Purification and separation of follicle stimulating hormone (FSH) and luteinising hormone (LH) from human menopausal gonadotrophin (hMG): 2. Preparation of biological apparently pure FSH by selective binding of the LH with an anti-hCG serum and subsequent chromatography. Acta Endocrinol 1996; 52:186–198.
12. Howles CM, Barri P, Cittadini E et al. Metrodin HP: clinical experiences with a new highly purified follicle stimulating hormone preparation suitable for subcutaneous administration. In: Lunenfeld B, editor. FSH Alone in Ovulation Induction. New York Parthenon Publishing Group, 1992: 45–61.
13. Gast M. Efficacy of FSH (metrodin HP) in hypothalamic pituitary dysfunction. Presented at the First Annual Meeting of the European Society for Gynaecologic and Obstetric Investigation. Madonna di Campiglio, Italy. February 912, 1992.
14. Dore PC, Rice C, Killick S. Human gonadotrophin preparations may cause allergic reaction. BMJ 1994; 308: 1509–1510.
15. Howles CM, Loumaye E, Giroud D et al. Multiple follicular development and ovarian steroidogenesis following subcutaneous administration of a highly purified urinary FSH preparation in pituitary desensitized women undergoing I V F a multicentre European phase III study. Hum Reprod 1994; 9: 424–430.
16. Wickland M. Borg J. Hamberger L et al. Simplification of IVF: minimal monitoring and the use of subcutaneous highly purified FSH administration for ovulation induction. Hum Reprod 1994; 9:1430–1436.
17. Howles CM. Genetic engineering of human FSH (gonal-F) Hum Reprod Update 1996; 2: 172–191.
18. Pierce JG, Parsons TF. Glycoprotein hormones: structure and function. Ann Rev Biochem 1991; 50: 465–495.
19. Chappel S, Kelton C, Nugent N. Expression of human gonadotropins by recombinant DNA methods. In: Genazzani AR, Pertaaglia F. editors. Proceedings of the 3rd World Congress on Gynecological Endocrinology. Parthenon Publishing Group, Carnforth UK, 1992: 179–184.
20. Loumaye E. Campbell R, Salat-Baroux J. Human follicle stimulating hormone produced by recombinant DNA technology: a review for clinicians. Hum Reprod Update 1995; 1:188–199.
21. Recombinant Human FSH Study Group. Clinical assessment of recombinant human follicle-stimulating hormone in stimulating ovarian follicular development before in vitro fertilisation. Fertil Steril 1995; 63:77–86.
22. Out HJ, Mannaerts BMJL, Driessen SGAJ, Coelingh Benninck HJT. Recombinant follicle stimulating hormone (rFSH; Puregon) in assisted reproduction: more oocytes, more pregnancies. Results from five comparative studies. Hum Reprod Update 1996; 2: 162–171.
23. Out HJ, Reimitz PE, Coelingh Bennink HJT. A prospective, randomised, multicentre study comparing recombinant FSH (Puregon) either given intramuscularly of subcutaneously in subjects undergoing IVF [abstract]. Hum Reprod 1995; 10: 6.
24. Albano C, Smitz J, Camus M et al. Pregnancy and childbirth in an in-vitro fertilization cycle after controlled ovarian stimulation in a woman with a history of allergic reaction to human menopausal gonadotropin. Him Reprod 1996; 11: 1632–1634. 179–184.
25. Bergh C, Howles CM, Borg K et al. Recombinant human follicle stimulating hormone (r-hFSH; Gonal-F®): results of a randomized comparative study in women undergoing asisted reproductive techniques. Hum Reprod 1997; 12: 2133–2139.
26. Steelman SL, Pohley FM. Assay of the follicle stimulating hormone based on the augmentation with human chorionic gonadotrophin. Endocrinology 1953; 53: 604–616.
27. De Leeuw R, Mulders J, Voortman G, Rombout F, Damm J, Kloosterboer L. Structure-function relationship of recombinant follicle stimulating hormone (Puregon ®). Mol Hum Rep 1996; 2:.
28. Lambert A, Talbot JA, Anobile CJ, Robertson WR. Gonadotrophin heterogeneity and biopotency: implications for assisted reproduction. Mol Hum Reprod 1998; 4: 619–629.
29. Lambert A, Rodgers M, Mitchell R et al. In-vitro biopotency and glycoform distribution of recombinant human follicle stimulating hormone (Org 32489), Metrodin and Metrodin-HP. Hum Reprod 1995; 10: 1928–1935.
30. Le Cotonne C, Porchet H, Beltrami V et al. Clinical pharmacology of recombinant human follicle–stimulating hormone (FSH) i. Comparative pharmacokinetics with urinary human FSH. Fertil Streril 1994; 61: 669–678 and ii. Single doses and steady state pharmacokinetics. Fertil Steril 1994; 61: 679–686.
31. Out HJ, Mannerts BMJL, Driessen SGAJ, Coelingh Benninck HJT. A prospective randomised assessor-blind, multicentre study comparing recombinant and urinary follicle stimulating hormone (Puregon vs. Metrodin) in in-vitro fertilisation. Hum Reprod 1995; 10: 2534–2540.
32. Devroey P, Tournaye H, Van Steirteghem A et al. The use of a 100IU starting dose of recombinant follicle stimulating hormone (Puregon ®) in in-vitro fertilisation. Hum Reprod 1998; 13: 565–566.
33. Recombinant Human FSH Study Group. Clinical assessment of rFSH in stimulating ovarian follicular development before IVF. Fertil Steril 1995; 63: 77–86.
34. Waterstone J, Parsons J, Bolton V. Elective transfer of two embryos. Lancer 1991; 337: 975–976.
35. Staessen C, Janssenswillen C, van den Abbeel E et al. Avoidance of triplet pregnancies by elective of two good quality embryos. Hum Reprod 1993; 8: 1650–1653.
36. Jansen CAM, Van Os HC. Puregon without analogues: an oxymoron. Gynaecol Endocrionol 1996; 10 (Suppl 1): 34.
37. Daya S, Gunby J, Hughes EG, Collins JA, Sagle MA. Follicle-stimulating hormone versus human menopausal gonadotropin for in vitro fertilsation cycles: a meta-analysis. Fertil Sreril 1995: 64: 347–354.
38. Loumaye E, Martineau I, Piazzi A et al. Clinical assessment of human gonadotrophins produced by recombinant DNA technology. Hum Reprod 1996; 11: 95–107.
39. Mercan R, Mayer Jacob F et al. Improved oocyte quality is obtained with follicle stimulating hormone alone than with follicle stimulating hormone human menopausal gonadotrophin combination. Hum Reprod 1997; 12: 1886–1889.
40. Hayden CJ, Rutherford AJ, Balen AHB. Induction of ovulation using a starting dose of 50 units of recombinant human follicle stimulating hormone (Puregon). Fertil Steril 1999; 71:106–108.
41. Van Weissenbruch MM, Schoemaker HC, Drexhage HA, Shoemaker J. Pharmacodynamics of human menopausal gonadotrophin (HMG) and follicle stimulating hormone (FSH). The importance of the FSH concentration in initiating follicular growth in polycystic ovary-like disease. Hum Reprod 1993; 8: 813–821.
42. Hornnes P, Giroud D, Howles C, Loumaye E. Recombinant human follicle-stimulating hormone treatment leads to normal follicular growth, estradiol concentration. and pregnancy in a World Health Group II anovulatory woman. Fertil Steril 1993; 60: 724–726.
43. Coelingh Bennick HJT, Fauser BCJM, Out HJ. Recombinant follicle stimulating hormone (FSH; Puregon) is more efficient than urinary FSH (Metrodin) in women with clomiphene citrate-resistant. normagonadotropic. chronic anovulation: a prospective, multicenter. assessor-blind, randomized, clinical trial. Fertil Steril 1998; 69.19–25.
44. Balen AH, Tan SL, Jacobs HS. Hypersecretion of luteinising hormone: a significant cause of infertility and miscarriage. Br J Obstet Gynaecol 1993; 100: 1082–1089.
45. Balen AH. Polycystic ovary syndrome: mode of treatment. In: Shoham Z, Howles CM, Jacobs HS, editors. Female Infertility Therapy: Current Practice. London: Martin Dunitz Ltd, 1999.
46. Richards JS. Estradiol receptor content in rat granulosa cells during follicular development: modification of estradiol and gonadotrophins. Endocrinology 1975; 97: 1174–1184.
47. Schoot DC, Coelingh Benninck HIT et al. Human recombinant follicle-stimulating hormone induces growth of preovulatory follicles without concommitant increase in androgen and estrogen biosynthesis in a woman with isolated gonadotrophin deficiency. J Clin Endocrinol Metab 1992; 74: 1471–1473.
48. Kousta E, White DM, Piazzi A, Loumaye E, Franks S. Successful induction of ovulation and completed pregnancy using recombinant human luteinizing hormone and follicle–stimulating hormone in a woman with Kallman's syndrome. Hum Reprod 1996; 11: 70–71.
49. Loumaye E, Martineau I, Piazzi et al. Clinical assessment of human gonadotrophins produced by recombinant DNA technology. Hum Reprod 1996; 11 (Suppl 11): 95–107.
50. Fares FA, Suganuma N, Nishimori K, La Polt PS, Hsueh AJW, Boime I. Design of a long-acting follitropin agonist by fusing the C-terminal sequence of the chorionic gonadotrophin beta subunit to the follitropin beta subunit. Proc Natl Acad Sci USA 1992; 89: 4304–4308.
51. Gast MJ. Evolution of clinical agents for ovulation induction. Am J Obstet Gynecol 1995; 172: 753–759.